AI-generated summary
The authors report a single-center, open-label prospective trial of a 532-nm picosecond laser in 25 subjects with pigmented lesions on the face and hands, 23 of whom completed the study. They report good-to-excellent clearance at 1 and 3 months in at least 95% of lesions, mild pain, transient side effects, and high subject satisfaction. The study had no control group and a small sample.
- Participants
- 25
- Who or what was studied
- Adults with pigmented lesions from chronic UV photoaging on the face and dorsal hands, Fitzpatrick skin types I-III
- Wavelengths
- 532 nm
- Limits stated in the abstract
- The study was single-center, open-label, had no control group, and enrolled only 25 subjects, 23 of whom completed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.lww.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 532 nm
- Energy density (fluence)
- 0.6J/cm2
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Wavelength, Fluence, Melanin. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.